Vestmark Advisory Solutions Inc. Takes Position in Teladoc Health, Inc. (NYSE:TDOC)

Vestmark Advisory Solutions Inc. acquired a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 319,785 shares of the health services provider’s stock, valued at approximately $6,891,000.

Other hedge funds have also modified their holdings of the company. Hexagon Capital Partners LLC raised its stake in Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after purchasing an additional 1,065 shares during the period. RIA Advisory Group LLC acquired a new stake in shares of Teladoc Health during the 4th quarter worth $36,000. GAMMA Investing LLC acquired a new stake in shares of Teladoc Health during the 4th quarter worth $41,000. Byrne Asset Management LLC purchased a new position in shares of Teladoc Health in the 3rd quarter worth $60,000. Finally, Van ECK Associates Corp boosted its holdings in Teladoc Health by 20.3% in the fourth quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock valued at $77,000 after acquiring an additional 606 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Stock Down 1.6 %

TDOC stock traded down $0.21 during midday trading on Friday, hitting $12.78. 6,206,900 shares of the company’s stock were exchanged, compared to its average volume of 5,358,721. The firm has a 50 day moving average price of $14.40 and a 200-day moving average price of $17.51. Teladoc Health, Inc. has a 12-month low of $12.53 and a 12-month high of $30.41. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -9.06 and a beta of 0.97. The company has a current ratio of 3.82, a quick ratio of 3.47 and a debt-to-equity ratio of 0.67.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The company had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.90%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.37) EPS. On average, analysts anticipate that Teladoc Health, Inc. will post -1.04 EPS for the current year.

Insider Transactions at Teladoc Health

In other news, COO Michael Willem Waters sold 5,793 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.69, for a total transaction of $73,513.17. Following the transaction, the chief operating officer now owns 64,881 shares of the company’s stock, valued at $823,339.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Teladoc Health news, CTO Nikolaos P. Nanis sold 2,866 shares of Teladoc Health stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $41,614.32. Following the completion of the transaction, the chief technology officer now owns 69,850 shares of the company’s stock, valued at $1,014,222. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael Willem Waters sold 5,793 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $12.69, for a total transaction of $73,513.17. Following the sale, the chief operating officer now directly owns 64,881 shares in the company, valued at $823,339.89. The disclosure for this sale can be found here. In the last 90 days, insiders sold 138,368 shares of company stock valued at $1,989,227. Insiders own 0.95% of the company’s stock.

Wall Street Analysts Forecast Growth

TDOC has been the subject of several research analyst reports. Royal Bank of Canada dropped their price target on Teladoc Health from $25.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company cut their price target on shares of Teladoc Health from $17.00 to $15.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. Truist Financial dropped their price objective on shares of Teladoc Health from $23.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, March 6th. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a report on Friday, April 26th. Finally, Citigroup lowered their price target on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, February 21st. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $18.73.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.